Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF trap) to inhibit vascular endothelial growth factor activity Journal Article
| Authors: | Konner, J.; Dupont, J. |
| Article Title: | Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF trap) to inhibit vascular endothelial growth factor activity |
| Abstract: | Primary tumors and metastases require blood vessel formation to support their continued growth and eventual metastasis. They use existing vasculature during initial growth but eventually must orchestrate the development and maintenance of new vessels - a process termed angiogenesis - to grow beyond a small size and spread. Angiogenesis is regulated by a number of soluble factors, the relative proportions of which can exacerbate or inhibit the process. Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis, produced by the majority of human solid tumors. Inhibitors of VEGF might have an impact on the growth and metastasis of these cancers. The relevance of this strategy to the treatment of colorectal cancer was first successfully demonstrated in human clinical trials using a monoclonal antibody against VEGF. A potent antiangiogenic soluble recombinant decoy, VEGF Trap is a protein constructed from VEGF receptor-binding domains linked to an immunoglobulin G1 constant region. It possesses an affinity for VEGF that is significantly higher than that of the monoclonal anti body. VEGF Trap has demonstrated marked efficacy in halting angiogenesis and shrinking tumors in preclinical animal models and is currently being studied in phase 1 clinical trials in humans with advanced solid malignancies. |
| Keywords: | vasculotropin; treatment outcome; survival analysis; vascular endothelial growth factor a; unclassified drug; clinical trial; angiogenesis inhibitor; bevacizumab; fluorouracil; placebo; ascites; cancer combination chemotherapy; dose response; drug efficacy; nonhuman; solid tumor; receptors, vascular endothelial growth factor; drug targeting; neoplasm staging; sensitivity and specificity; binding affinity; colorectal cancer; animals; mice; vasculotropin receptor; metastasis; risk factors; antineoplastic activity; dose-response relationship, drug; vasculotropin inhibitor; vasculotropin receptor 2; angiogenesis; neovascularization, pathologic; irinotecan; monoclonal antibody; drug receptor binding; colorectal neoplasms; disease model; cancer inhibition; hypotension; antibodies, monoclonal; folinic acid; malignant neoplastic disease; drug bioavailability; immunoglobulin g1; drug half life; disease models, animal; drug dose regimen; tyrosine kinase; tumor vascularization; vasculotropin antibody; vasculotropin receptor 1; solubility; pegaptanib; monoclonal antibody dc101; immunoglobulin fc fragment; clinical trials, phase i; humans; human; article; antiagiogenesis; antitumor effects; decoy receptor; heparin-binding domains; vasculotropin receptor 2 antibody; vasculotropin trap |
| Journal Title: | Clinical Colorectal Cancer |
| Volume: | 4 |
| Issue: | Suppl.2 |
| ISSN: | 1533-0028 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2004-10-01 |
| Start Page: | S81 |
| End Page: | S85 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 15479484 |
| DOI/URL: | |
| Notes: | Clin. Colorectal Cancer -- Cited By (since 1996):63 -- Export Date: 16 June 2014 -- CODEN: CCCLC C2 - 15479484 -- Source: Scopus |
Citation Impact
Related MSK Work